Computational protocol: Association between cerebral dopamine neurotrophic factor (CDNF) 2 polymorphisms and schizophrenia susceptibility and symptoms in the Han Chinese population

Similar protocols

Protocol publication

[…] Stage 1 samples were those from our previous publications [, ], and included 528 paranoid SZ patients (mean age: 27.32 ± 8.03 years old) and 528 healthy controls (mean age: 27.73 ± 8.01 years old) who were recruited from March 2005 to December 2008. Stage 2 samples included 142 SZ patients (paranoid, n = 122 and undifferentiated, n = 20; mean age: 29.28 ± 7.17 years old) and 173 healthy controls (mean age: 32.49 ± 7.43 years old) who were recruited from May 2011 to December 2014.SZ was diagnosed as previously described [, ] according to the criteria listed in the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV). Exclusion criteria were as follows: patients had been diagnosed with other psychiatric disorders; or had organic brain disease, substance dependence, severe medical complications, or neurological diseases. Family mental health history (FH) was defined as at least one first- or second-degree relative of the proband who met DSM-IV criteria for SZ or schizoaffective disorder. The Positive and Negative Symptom Scale (PANSS) was used to evaluate psychotic syndromes. Five factors were derived from the PANSS, including positive symptoms, negative symptoms, cognition, expression/anxiety, and excitement/hostility [].A total of 372 SZ patients (stage 1, n = 229 and stage 2, n = 143) who were not taking antipsychotic medications were evaluated for psychotic syndromes using the PANSS []. Inclusion and exclusion criteria for healthy controls were as described our previous papers [, ]. These subjects were screened by psychiatrists in simple non-structured interviews. All participants were unrelated Han Chinese who were born and living in North Henan province.Five SNPs were selected as described in our previous work [, ] and covered the 26974145–26995906 genomic intron region on chromosome 10. In stage 1, genotyping was carried out as detailed in our earlier studies [, ] using Illumina GoldenGate assays on a BeadStation 500G Genotyping System (Illumina, San Diego, CA, USA). In stage 2, samples were genotyped using a standard Illumina genotyping protocol.Statistical analyses in this study were performed as described in our previous papers [, ]. Power analyses were performed using the G*Power software to calculated (http://www.gpower.hhu.de/) for this study [, ]. Genotype and allele frequencies were analyzed using Haploview v.4.1. Hardy–Weinberg equilibrium was assessed with the χ2 test with one degree of freedom. Associations between the five factors from the PANSS and different genotype carriers were evaluated by analysis of variance. Bonferroni correction for multiple pair-wise comparisons was conducted for the X × phenotype interaction to reduce the probability of false positives. P < 0.05 was considered statistically significant. The corrected α′ (P = 0.01) is α (P = 0.05) divided by the number of possible comparisons. […]

Pipeline specifications

Software tools G*Power, Haploview
Applications Miscellaneous, GWAS
Organisms Homo sapiens
Chemicals Dopamine